FDA approves first plasmid DNA immunotherapy for recurrent respiratory papillomatosis
FDA grants accelerated approval to Voceryq, the first plasmid DNA immunotherapy, for recurrent respiratory papillomatosis; Medline exits the bed market after an FDA early alert; and an Illinois man pleads guilty to $227M Medicare fraud.
FDA approves Instylla’s Embrace hydrogel embolic for peripheral arterial bleeds
FDA approves an expanded indication for Instylla’s Embrace hydrogel embolic to treat peripheral arterial bleeds; a federal judge strikes CMS’s narrowed medically frail Medicaid exemption; and DOL finalizes its PBM fee-disclosure rule.